LONDON - Ananda Developments PLC (AQSE: ANA), a life sciences company specializing in the development of cannabidiol (CBD) based therapies, has announced the publication of a research article in the peer-reviewed journal Trends in Pharmacological Science (TIPS). The article, titled 'Endometriosis: cannabidiol therapy for symptom relief,' explores the potential of CBD as a treatment for endometriosis, a condition affecting an estimated 10% of women globally.
Authored by a team including Dr. Lucy Whitaker and Professors Andrew Horne and Philippa Saunders of the University of Edinburgh, alongside Professor Clive Page and Charles Morgan of Ananda, the article reviews data from patient samples and animal models. It focuses on the pathophysiology of endometriosis and the pathways where CBD has shown activity. The article also discusses the pharmacokinetics of CBD formulations and their use in ongoing clinical trials for endometriosis and other pain conditions.
Charles Morgan, Chairman of Ananda, expressed optimism about the findings, stating, "The potential of CBD as a safe, efficacious and cost-effective treatment for the symptoms of endometriosis is compelling." He added that Ananda looks forward to collaborating with the University of Edinburgh on the upcoming ENDOCAN clinical trial.
The research highlights CBD's analgesic, anti-inflammatory, immunomodulatory, anti-angiogenic, antiproliferative, and neuroprotective effects. Ananda aims to develop a licensed CBD-based medicine for endometriosis symptoms, with the goal of making it available on the National Health Service (NHS).
TIPS is recognized as a top-tier scientific journal, ranking in the upper 2% worldwide. The publication of this article marks a significant milestone for Ananda in its commitment to advancing CBD-based therapies.
Ananda Developments is listed on the AQSE Growth Market and is dedicated to the research and clinical development of CBD therapies for inflammatory pain conditions. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.